MorphoSys AG (WBO:MOR) Price-to-Tangible-Book : (As of May. 01, 2024)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Price-to-Tangible-Book?

As of today (2024-05-01), MorphoSys AG's share price is €66.15. MorphoSys AG's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was €-30.25. Hence, MorphoSys AG's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for MorphoSys AG's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, MorphoSys AG's highest Price to Tangible Book Ratio was 11.50. The lowest was 4.03. And the median was 6.37.

WBO:MOR's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.69
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, MorphoSys AG's share price is €66.15. MorphoSys AG's Book Value per Sharefor the quarter that ended in Dec. 2023 was €1.30. Hence, MorphoSys AG's P/B Ratio of today is 50.73.

MorphoSys AG Price-to-Tangible-Book Historical Data

The historical data trend for MorphoSys AG's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Price-to-Tangible-Book Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

11.70

5.59

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MorphoSys AG's Price-to-Tangible-Book

For the Biotechnology subindustry, MorphoSys AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Price-to-Tangible-Book falls into.

MorphoSys AG Price-to-Tangible-Book Calculation

MorphoSys AG's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	66.15	/	-30.248
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

MorphoSys AG Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.